Health: Report Calls For Increased Efforts On TB; WHO Warns About Antibiotic-Resistant Sexually Transmitted Disease 07/07/2017 Catherine Saez Tuberculosis is still a deadly killer, and a new report by two humanitarian organisations raises alarm on poor progress on the disease diagnosis and treatment. The report calls for governments to increase efforts to fight the disease, and for the G20 countries to mobilise funds to help, in particular to boost research and development for new treatments. Separately, the World Health Organization issued a call for new treatments to fight antibiotic resistant gonorrhoea. Continue reading -> G20: Security, Trade, Climate, Trump Diplomacy Overshadow Health, IT, Innovation 07/07/2017 Monika Ermert On the eve of the G20 meeting in Hamburg, Germany, German politicians described positions on free trade and climate as the most difficult issues. Expectations from civil society groups in the G20 results are modest at best and the 6 July protest march “Welcome to Hell” was cancelled after clashes between the police and parts of the protestors. Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
G20: Security, Trade, Climate, Trump Diplomacy Overshadow Health, IT, Innovation 07/07/2017 Monika Ermert On the eve of the G20 meeting in Hamburg, Germany, German politicians described positions on free trade and climate as the most difficult issues. Expectations from civil society groups in the G20 results are modest at best and the 6 July protest march “Welcome to Hell” was cancelled after clashes between the police and parts of the protestors. Continue reading -> Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Enter The African Medicines Agency, Continent’s First Super-Regulator? 03/07/2017 Tatum Anderson An African medicines agency, the continent’s first super-regulator, could be approved as soon as next year. Continue reading -> Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Medicines Patent Pool Nets WHO’s Kieny As New Chair 03/07/2017 Catherine Saez Marie-Paule Kieny, fresh out of the World Health Organization, where she held the position of assistant director general for Health Systems and Innovation, will be the new chair of the Medicines Patent Pool, as of 1 September. Continue reading -> Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Summit: Artificial Intelligence Is Humanity-Changing, Build Safeguards Now 07/06/2017 Catherine Saez For artificial intelligence enthusiasts, the future is bright. Soon intelligent machines will help humankind solve most problems, and according to one speaker at an artificial intelligence summit in Geneva this week, humans will be outsmarted by robots in the foreseeable future, in an artificial intelligence bliss. For others, artificial intelligence is far from delivering a fully positive outcome, and for several United Nations representatives, such as the World Health Organization, the world should not be entrusted to robots just yet. Continue reading -> Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Polypills: Are Miracle Treatments Being Overlooked? 05/06/2017 Tatum Anderson Cardiovascular diseases (CVD), a group of conditions that can result in heart attacks and strokes, is the world’s number one killer, accounting for one-third of deaths throughout the world, according to research released recently (17 May) by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. Continue reading -> Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Antimicrobial Resistance: PPPs The Way Forward, Speakers Say 25/05/2017 Catherine Saez With global funding for research and development decreasing, and the growing threat of antimicrobial resistance, ways to incentivise research are seen as key to solving the problem. Speakers at a side event to the World Health Assembly this week presented models of public and private partnerships to address the issue. Continue reading -> Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Expanding Access To Medicines: What Role For Transparency? 25/05/2017 Mara Pillinger Transparency” and “accountability” are familiar buzzwords. Like salt and pepper, they pop up on nearly every list of ingredients for sound policy and good governance. But, as Ilona Kickbusch and Suerie Moon of the Graduate Institute Global Health Centre in Geneva point out, their details are rarely specified: transparency for what? Accountability to whom? On Tuesday afternoon, those not busy casting a vote for the next World Health Organization director general got the chance to dig into these questions at a panel co-sponsored by the Graduate Institute and FIND. In particular, discussion focused on transparency in terms of public access to two types of information: drug R&D costs and clinical trial data. Continue reading -> Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
Draft Cancer Resolution Might Be Set For Approval At World Health Assembly 19/05/2017 Catherine Saez According to sources, countries have agreed in the nick of time on a draft resolution on cancer prevention, control, and access to cancer medicines, and in particular the price of new cancer medicines, to be examined at the World Health Assembly next week. Continue reading -> March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts
March-in Rights: A Lost Opportunity To Lower US Drug Prices 18/05/2017 Steven Seidenberg It appears not just unfair, but absurdly so. The US government paid for research that produced a patented drug, the patents were licensed exclusively to a Japanese firm, and that firm is now committing price discrimination against the US. Astellas Pharma is selling its anti-prostate cancer drug, Xtandi, for over $129,000 per year per patient in the United States – triple the price of the drug in Japan. Alas, this situation is not unusual. Many drugs that were financed by US taxpayers are sold in the US at exorbitant prices, but are much cheaper in other high-income industrialized nations. This differential price problem could be solved easily. However, the US government has consistently refused to exercise its march-in rights in order to lower drug prices. Continue reading -> Posts navigation Older postsNewer posts